{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:18:57Z","timestamp":1793837937938,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ejps.2021.105721","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:33:44Z","timestamp":1611056024000},"page":"105721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Improvement of lipid solubility and oral bioavailability of a poorly water- and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation"],"prefix":"10.1016","volume":"159","author":[{"given":"Shinya","family":"Okawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sumimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Ogawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105721_bib0001","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s11095-010-0309-1","article-title":"Nano-emulsions and microemulsions: Classifications of the critical differences","volume":"28","author":"Anton","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.105721_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.addr.2016.02.005","article-title":"Computational prediction of formulation strategies for beyond-rule-of-5 compounds","volume":"101","author":"Bergstrom","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.105721_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejps.2008.02.007","article-title":"Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutyl-ether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions","volume":"34","author":"Brewster","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105721_bib0004","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersatrurating drug delivery systems: The answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105721_bib0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/ed067p221","article-title":"The hydrolysis of monoprotic base: Some critical remarks","volume":"67","author":"Cardinali","year":"1990","journal-title":"J. Chem. Edu."},{"key":"10.1016\/j.ejps.2021.105721_bib0006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-5173(86)90027-X","article-title":"Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules","volume":"34","author":"Charman","year":"1986","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejps.2021.105721_bib0007","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/jps.23539","article-title":"Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions","volume":"102","author":"Chauhan","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105721_bib0008","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jphp.12984","article-title":"Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches \u2013 a PEARRL review","volume":"71","author":"Ditzinger","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105721_bib0009","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1021\/mp100117k","article-title":"Modifying the diffusion layer of soluble salts of poorly soluble basic drugs to improve dissolution performance","volume":"7","author":"Hawley","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2021.105721_bib0010","first-page":"32","article-title":"Self-microemulsifying DDS formulation (in Japanese)","volume":"70","author":"Higaki","year":"2010","journal-title":"J. Pharm. Sci. Technol. Japan."},{"key":"10.1016\/j.ejps.2021.105721_bib0011","unstructured":"Home Page of EVONIK https:\/\/healthcare.evonik.com\/product\/health-care\/en\/products\/pharmaceuitcal-excipients\/."},{"key":"10.1016\/j.ejps.2021.105721_bib0012","first-page":"2595","article-title":"Improvement of oral bioavailability of N-251, a novel antimalarial drug, by increasing lymphatic transport with long-chain fatty acid-based self-nanoemulsifying drug delivery system","volume":"32","author":"Imada","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.105721_bib0013","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.ddtec.2012.03.002","article-title":"Lipid-based formulations for oral delivery of lipophilic drugs","volume":"9","author":"Kuentz","year":"2012","journal-title":"Drug Discovery Today Technol"},{"key":"10.1016\/j.ejps.2021.105721_bib0014","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/open.201600015","article-title":"Melting point distribution analysis of globally approved and discontinued drugs: a research for improving the chances of success of drug design and discovery","volume":"5","author":"Mao","year":"2016","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.ejps.2021.105721_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.60.1.0008","article-title":"Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments","volume":"60","author":"McConnell","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105721_bib0016","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ejpb.2014.08.006","article-title":"In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623","volume":"88","author":"McEvoy","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.105721_bib0017","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2006.07.015","article-title":"Importance of bile acids for novel oral absorption system containing polyamines to improve intestinal absorption","volume":"115","author":"Miyake","year":"2006","journal-title":"J. Controlled Rel."},{"key":"10.1016\/j.ejps.2021.105721_bib0018","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejpb.2017.04.021","article-title":"Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery","volume":"117","author":"Morgen","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.105721_bib0019","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2013.03.054","article-title":"Lipid-based formulations for oral administrat-ion of poorly water-soluble drugs","volume":"453","author":"Mu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105721_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2008.09.027","article-title":"Novel oral absorption system containing polyamines and bile salts enhances drug transport via both transcellular and paracellular pathways across Caco-2 cell monolayers","volume":"367","author":"Mukaizawa","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105721_bib0021","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.addr.2007.10.014","article-title":"Enhancing intestinal drug solubilisation using lipid-based delivery systems","volume":"60","author":"Porter","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.105721_bib0022","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12272-014-0399-0","article-title":"Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability","volume":"38","author":"Pradhan","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejps.2021.105721_bib0023","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1021\/mp500790t","article-title":"Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations","volume":"12","author":"Sahbaz","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2021.105721_bib0024","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/js980403l","article-title":"Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs","volume":"88","author":"Serajuddin","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105721_bib0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/js980489i","article-title":"Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some n-acyloxymethyl phenytoin prodrugs","volume":"88","author":"Stella","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105721_bib0026","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/js980008v","article-title":"Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications","volume":"87","author":"Stella","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105721_bib0027","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.addr.2007.05.013","article-title":"Prodrug strategies to overcome poor water solubility","volume":"59","author":"Stella","year":"2007","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ejps.2021.105721_bib0028","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/j.2042-7158.2011.01360.x","article-title":"Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy","volume":"63","author":"Tung","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105721_bib0029","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpharm.2013.05.013","article-title":"Drug precipitation inhibitors in supersaturable formulations","volume":"453","author":"Xu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105721_bib0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0021-5198(19)43019-9","article-title":"Effect of OPC-12759, a Novel Antiulcer Agent, on Chronic and Acute Experimental Gastric Ulcer, and Gastric Secretion in Rats","volume":"49","author":"Yamasaki","year":"1989","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105721_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-2999(87)90649-2","article-title":"Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat","volume":"142","author":"Yamasaki","year":"1987","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105721_bib0032","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jps.2600720420","article-title":"Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs","volume":"72","author":"Yamaoka","year":"1983","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:57:02Z","timestamp":1760529422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":32,"alternative-id":["S0928098721000233"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105721","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of lipid solubility and oral bioavailability of a poorly water- and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105721"}}